SHR3680
Phase 3Small molecule
SHR3680 is one of 31 small molecule programs targeting Prostate Cancer. It is currently in Phase 3.
1
Indications
11
Total Trials
2
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
348 competitors in Prostate Cancer
#DrugCompanyPhaseTrials
1Radium-223
BayerPhase 3
Triptorelin Embonate
IpsenPhase 3
Lhrha
Johnson & JohnsonPhase 3
Docetaxel /m²
AstraZenecaPhase 3
Gallium Ga 68 Gozetotide
MMayo Clinic
Phase 3
Luteinizing Hormone Releasing Hormone
UUS Department of Veterans Affairs
Phase 3
SHR3680
JJiangsu HengRui Medicine Co., Ltd.
Phase 3
Lupron Depot
RRepros Therapeutics Inc.
Phase 3
Trexall
Jazz PharmaceuticalsPreclinical
Duragesic
CCephalon
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Prostate Cancer5 trials
Treatment3 trials
Impairment1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SHR3680. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details